Cipla's Pune Unit Loses Drug Licence Over Reactin Plus Issue

Cipla's Pune distribution unit is operating without valid drug sale licences after Maharashtra FDA cancelled them following an inspection that surfaced unauthorised labelling, recall compliance gaps, storage non-compliance, and stock record discrepancies tied to its Reactin Plus product line. For QA directors and regulatory leads managing multi-site operations, the action is a direct signal that concurrent failures across documentation, cold-chain controls, and post-market recall execution will draw cumulative enforcement rather than isolated notices.

The Maharashtra FDA's findings span four distinct compliance domains. Unauthorised labelling points to a breakdown in artwork change control, a process governed under 21 CFR Part 211.122 and its ICH Q10 equivalents, where label versions in circulation did not align with approved specifications. Recall compliance gaps suggest that the site's post-market surveillance loop, specifically the retrieval verification and reconciliation steps, did not meet the regulator's evidentiary standard. Storage non-compliance and stock record discrepancies compound the picture: together they indicate that inventory management and environmental monitoring controls were not functioning as a unified system.

Licence cancellation, as distinct from suspension, carries a harder administrative reset. The unit cannot legally sell scheduled drugs until licences are reinstated, a process that typically requires demonstrated corrective action, re-inspection, and regulatory sign-off. For Cipla's supply continuity planning, the Pune unit's status creates an immediate distribution gap that will need to be absorbed by alternate licensed sites or third-party logistics arrangements, each of which carries its own GMP documentation burden.

The broader compliance read for plant heads is the sequencing of failures. No single finding here is novel; unauthorised labelling, recall gaps, and storage deviations appear routinely in Form 483 observations and WHO inspection reports globally. What escalates enforcement to licence cancellation is the co-occurrence of failures that, taken together, suggest systemic quality management breakdown rather than isolated procedural lapses. Sites carrying open CAPAs across labelling, recall, and storage simultaneously should treat this action as a benchmark for regulator tolerance thresholds.

Reinstatement timelines and the scope of Cipla's corrective and preventive action plan will be the measurable outcomes to track as this enforcement cycle closes.

Source: Indian Pharma Post via Media4Growth, 28 August 2026.